MedTrace Logo

Multiple-dose Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Pharmacodynamics of HSK7653 in T2DM

NCT06059326 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2023-09-28

No results posted yet for this study

Summary

To evaluate the safety, tolerability and pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of HSK7653 tablets in Type 2 Diabetes Mellitus Patients.

Conditions

Interventions

DRUG

HSK7653 10 mg

Tablet, HSK7653 10 mg Q2W, 12 weeks

DRUG

HSK7653 25 mg

Tablet, HSK7653 25 mg Q2W, 12 weeks

DRUG

HSK7653 50 mg

Tablet, HSK7653 50 mg Q2W, 12 weeks

DRUG

Placebo

Tablet, 0 mg Q2W, 12 weeks

Sponsors & Collaborators

  • Haisco Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-22
Primary Completion
2019-11-05
Completion
2019-11-05

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06059326 on ClinicalTrials.gov